New combo therapy targets Hard-to-Treat cancers
NCT ID NCT04421820
First seen Feb 01, 2026 · Last updated Apr 30, 2026 · Updated 12 times
Summary
This study tests a new drug called BOLD-100 combined with standard FOLFOX chemotherapy in people with advanced colorectal, pancreatic, stomach, or bile duct cancers that have spread or cannot be removed. The goal is to see if the combination is safe and can shrink tumors or slow cancer growth. About 220 adults will take part, first in a small dose-finding group and then in a larger group to measure effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cross Cancer Institue
RECRUITINGEdmonton, Alberta, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
Jewish General Hospital
RECRUITINGMontreal, Quebec, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
Juravinski Cancer Centre
RECRUITINGHamilton, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
Kangbuk Samsung Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mater Miserecordiae University Hospital
RECRUITINGDublin, Ireland
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
McGill University Health Centre Glen Site
RECRUITINGMontreal, Quebec, Canada
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Moffitt Cancer Center
COMPLETEDTampa, Florida, 33612, United States
-
National Cancer Center
RECRUITINGGoyang, South Korea
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Severance Hospital - Yonsei University
RECRUITINGSeoul, South Korea
Contact Email: •••••@•••••
-
St. James Hospital
RECRUITINGDublin, Ireland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
St. Vincent's University Hospital
RECRUITINGDublin, Ireland
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact
-
The Ottawa Hospital Cancer Centre
RECRUITINGOttawa, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California, Los Angeles
COMPLETEDSanta Monica, California, 90095, United States
Conditions
Explore the condition pages connected to this study.